Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05044819

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Status
Active Not Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
154 (actual)
Sponsor
Jazz Pharmaceuticals · Industry
Sex
All
Age
1 Year
Healthy volunteers
Not accepted

Summary

This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.

Conditions

Interventions

TypeNameDescription
DRUGCannabidiolOral Cannabidiol solution 100 mg/mL

Timeline

Start date
2021-07-07
Primary completion
2027-08-01
Completion
2028-03-31
First posted
2021-09-16
Last updated
2026-03-17

Locations

26 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05044819. Inclusion in this directory is not an endorsement.

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution (NCT05044819) · Clinical Trials Directory